Get all your news in one place.

100’s of premium titles.
One app.

Start reading

Get all your news in one place.

100’s of premium titles. One news app.

Start reading

The Latest Breaking News from Vertex Pharmaceuticals

Vertex Pharmaceuticals Receives Composite Rating Upgrade

The IBD SmartSelect Composite Rating for Vertex Pharmaceuticals increased from 94 to 96 Tuesday.

Investors Business Daily

What 5 Analyst Ratings Have To Say About Vertex Pharmaceuticals

Over the past 3 months, 5 analysts have published their opinion on Vertex Pharmaceuticals (NASDAQ:VRTX) stock. These analysts are typically employed by large Wall Street banks and tasked with understanding a company's business to predict how a stock will trade over the upcoming year.

Benzinga

2 Recession Stocks to Buy Right Now

Multi-decade-high inflation and aggressive Fed rate increases might push the economy into a recession. So, investors looking to mitigate a market downturn should invest in Dollar Tree (DLTR) and Vertex Pharmaceuticals (VRTX), as they could deliver stable returns because their businesses enjoy a near-inelastic demand.

StockNews.com

From analysis to the latest developments in health,
read the most diverse news in one place.

Why Vertex Pharma's Pipeline Has Never Been More Important

Vertex will need to lean on its pipeline to prop VRTX stock, an analyst said Thursday after the company delivered a mixed report.

Investors Business Daily

Analyst Ratings for Vertex Pharmaceuticals

Over the past 3 months, 4 analysts have published their opinion on Vertex Pharmaceuticals (NASDAQ:VRTX) stock. These analysts are typically employed by large Wall Street banks and tasked with understanding a company's business to predict how a stock will trade over the upcoming year.

Benzinga

Analyzing Vertex Pharmaceuticals's Short Interest

Vertex Pharmaceuticals's (NASDAQ:VRTX) short percent of float has risen 18.8% since its last report. The company recently reported that it has 4.01 million shares sold short, which is 1.58% of all regular shares that are available for trading.

Benzinga

Benzinga's Top Ratings Upgrades, Downgrades For May 3, 2022

Upgrades

Benzinga

Read news from The Economist, FT, and more,
with one subscription

Dow Jones Gains; These Warren Buffett Stocks Charge; Pharma Leader Hit By This Surprise Move

The Dow Jones fell as the 10-year treasury yield spiked., A couple of Warren Buffett stocks popped higher. Intel led the blue chips.

Investors Business Daily

$1000 Invested In Vertex Pharmaceuticals 5 Years Ago Would Be Worth This Much

Vertex Pharmaceuticals (NASDAQ:VRTX) has outperformed the market over the past 5 years by 6.39% on an annualized basis producing an average annual return of 17.51%. Currently, Vertex Pharmaceuticals has a market capitalization of $65.74 billion.

Benzinga

Why Vertex Pharmaceuticals Shares Are Falling

Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) shares are trading lower by 3.42% to $263.88 during Monday’s pre-market session after the company announced VX-880 Phase 1/2 has been placed on clinical hold by the FDA due to “a determination that there is insufficient information to support do

Benzinga

If You Invested $1000 In Vertex Pharmaceuticals 15 Years Ago, Here's How Much You Would Have Today

Vertex Pharmaceuticals (NASDAQ:VRTX) has outperformed the market over the past 15 years by 8.29% on an annualized basis producing an average annual return of 15.84%. Currently, Vertex Pharmaceuticals has a market capitalization of $72.91 billion.

Benzinga

Dow Jones Falls; Tesla Rises Despite 'Exceptionally Difficult Quarter'; Twitter Soars On Musk Stake

The Dow Jones Industrial Average fell Monday, as Tesla climbed after the company reported record vehicle deliveries.

Investors Business Daily

$100 Invested In Vertex Pharmaceuticals 15 Years Ago Would Be Worth This Much

Vertex Pharmaceuticals (NASDAQ:VRTX) has outperformed the market over the past 15 years by 7.35% on an annualized basis producing an average annual return of 15.26%. Currently, Vertex Pharmaceuticals has a market capitalization of $67.63 billion.

Benzinga

Dow Jones Rallies After March Jobs Report Miss; Treasury Yields Surge

The Dow Jones Industrial Average rallied Friday after the March jobs report miss. The 10-year Treasury yield surged.

Investors Business Daily

Get all your
news in one place.

100’s of premium titles.
One news app.

Investors Business Daily

Dow Jones Falls As Biden Taps Emergency Oil, Inflation Gauge Hits 39-Year High; Pharma Leader Pops

The Dow Jones fell as President Joe Biden tapped the nation's emergency oil reserves. The Fed's favorite inflation gauge spiked.

Investors Business Daily

Dow Jones Continues To Pull Back After Recent Rally; Investors Await Biden's Release Of Oil Reserves

Elsewhere, Paychex rose over 1% and moved above a proper buy point.

Benzinga

Vertex Touts Positive Data From Mid-Stage Study Of Its Non-Opioid Pain Drug

Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) released positive results from two Phase 2 post-operative trials for its non-opioid program, VX-548. One trial looked at patients who had just received a bunionectomy (Correcting the deformity of toes & foot), the other in patients who received abdominoplasty (tummy tuck). Vertex said that within 48 hours of surgery,…

Investors Business Daily

Stock Market Falls As Biden To Release Oil Reserves; Key Inflation Rate Rises

The stock market traded lower as President Biden prepared to release oil reserves, sending oil prices lower.

Get all your
news in one place.

100’s of premium titles.
One news app.

Investors Business Daily

Dow Jones Falls As Biden Touts This Tax Hike; Tesla Soars Despite Covid Shutdown; AMC Stock Explodes

The Dow Jones fell after President Biden unveiled tax hikes. Tesla stock soared on split news. Microsoft was up while AMC stock exploded.

Investors Business Daily

IBD Screen Of The Day: 3 Stocks Near Buy Points With Rising Profit Estimates

Vertex Pharmaceuticals has been outperforming and ranks second in the biotech industry group.

Benzinga

$1000 Invested In Vertex Pharmaceuticals 5 Years Ago Would Be Worth This Much

Vertex Pharmaceuticals (NASDAQ:VRTX) has outperformed the market over the past 5 years by 9.35% on an annualized basis.

Investors Business Daily

UnitedHealth, Vertex Lead Five Stocks Looking Healthy In A Weak Market

UnitedHealth and Vertex Pharmaceuticals are among five medical stocks with healthy action in a weak market.

Benzinga

This Biopharmaceutical Company Has A Better 1-Year Return Than Tesla, Apple, Starbucks, Nvidia And Microsoft

Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) creates new possibilities via medicine to cure diseases and improve people's lives, and over the past year, marked gains in investors’ portfolios.

Benzinga

Recap: Vertex Pharmaceuticals Q4 Earnings

Vertex Pharmaceuticals (NASDAQ:VRTX) reported its Q4 earnings results on Wednesday, January 26, 2022 at 04:01 PM. Here's what investors need to know about the announcement.

Investors Business Daily

Vertex Pharma Nears Year-High As Bullish Outlook, Pipeline Promise Spark Shares

Vertex Pharmaceuticals issued a bullish 2022 outlook, leading VRTX stock to approach a 12-month high early Thursday.

1 … 5 6 7 8

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.